<DOC>
	<DOCNO>NCT02010970</DOCNO>
	<brief_summary>This study single-center , open-label , 3-group , fixed-sequence drug-drug interaction study assess effect coadministration multiple-dose itraconazole diltiazem single-dose PK AZD3293 effect coadministration single- multiple-dose AZD3293 single-dose PK midazolam . The study also evaluate safety tolerability single multiple oral dos AZD3293 , alone combination itraconazole , diltiazem , midazolam healthy young subjects.AZD3293 develop treatment Alzheimer 's disease</brief_summary>
	<brief_title>A Phase I Study Healthy Volunteers Assess Effect Cytochrome3A4 ( CYP3A4 ) Inhibitors ( Diltiazem Itraconazole ) Pharmacokinetics ( PK ) AZD3293 Effects AZD3293 Pharmacokinetics Midazolam , Cytochrome 3A4 Cytochrome 3A5 ( CYP3A4/CYP3A5 ) Substrate</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Provision sign , write , date informed consent prior studyspecific procedure Male nonfertile female healthy subject , age 18 55 year time consent Body weight ≥50 ≤100 kg body mass index ( BMI ) ≥19 ≤30 kg/m2 Clinically normal finding physical examination relation age , judge Investigator Male healthy subject must willing use barrier contraception , ie , condom , even partner postmenopausal , surgically sterile , use accept contraceptive method , first day dose 3 month last dose investigational product ( IP ) Participation prior study AZD3293 History clinically significant disease disorder , opinion Investigator , may put subject risk participation study , may influence result , may limit subject 's ability participate study History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug History previous ongoing psychiatric disease/condition include psychosis , affective disorder , anxiety disorder , borderline state personality disorder accord criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) , assess MiniInternational Neuropsychiatric Interview ( MINI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>phase I</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>AZD3293</keyword>
	<keyword>itraconazole</keyword>
	<keyword>diltiazem</keyword>
	<keyword>medazolam</keyword>
	<keyword>drug interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>